Who Should Not Take Nebivolol: Contraindications and Cautions
Nebivolol is a modern beta-blocker prescribed in the UK for high blood pressure and, in older adults, for stable chronic heart failure. It is generally well tolerated, but there are clear situations in which it should not be used or requires special care. Our editorial team summarises the contraindications and cautions that doctors and pharmacists consider.
How nebivolol differs from older beta-blockers
Beta-blockers reduce the effects of adrenaline and noradrenaline on the heart, slowing heart rate and reducing the force of contraction. Nebivolol is highly selective for beta-1 receptors, which are found mainly in the heart, and has relatively little effect on beta-2 receptors in the airways and blood vessels at standard doses.
Uniquely among commonly used beta-blockers, nebivolol also promotes the release of nitric oxide from the blood vessel lining, causing vasodilation. A review by Münzel and Gori (2009) described it as "somewhat different" for this reason. This dual action may explain why it tends to cause less fatigue and cold extremities than older agents.
In the UK, nebivolol is licensed for essential hypertension and for stable mild to moderate chronic heart failure in patients aged 70 and over, as an add-on to standard therapy. The latter indication is based on the SENIORS trial (Flather et al., 2005), which showed a reduction in the combined outcome of death or cardiovascular hospitalisation.
NICE guideline NG136 does not place beta-blockers as first-line treatment for uncomplicated hypertension, but they remain important when there are additional reasons to use them, such as heart failure, angina or certain arrhythmias.
Absolute contraindications
According to the UK summary of product characteristics, nebivolol should not be used in several situations. These are conditions in which reducing heart rate or blocking adrenaline could be dangerous.
- Hypersensitivity to nebivolol or any tablet ingredient.
- Liver insufficiency or impaired liver function.
- Acute heart failure, cardiogenic shock or decompensated heart failure requiring intravenous inotropic support.
- Sick sinus syndrome, including sino-atrial block.
- Second- and third-degree heart block without a pacemaker.
- History of bronchospasm or bronchial asthma.
- Untreated phaeochromocytoma.
- Metabolic acidosis.
- Bradycardia (resting heart rate below 60 beats per minute before treatment).
- Hypotension (systolic blood pressure below 90 mmHg).
- Severe peripheral circulatory disturbances.
The liver contraindication is specific to nebivolol among commonly used beta-blockers. The drug is extensively metabolised by the liver, particularly through the CYP2D6 enzyme, and its levels can rise substantially when liver function is impaired.
The asthma contraindication reflects the general caution with beta-blockers. Even selective agents can provoke bronchospasm in susceptible people, and in asthma this can be life-threatening.
Situations requiring caution
Beyond absolute contraindications, several conditions require careful monitoring rather than outright avoidance. The decision is made by the prescriber, who weighs the benefits against the risks for each patient.
| Condition | Concern | Typical approach |
|---|---|---|
| Diabetes | May mask signs of hypoglycaemia such as tremor and palpitations | More frequent glucose monitoring |
| COPD | Possible airway narrowing | Cardioselective agents often tolerated; careful review |
| Hyperthyroidism | May mask tachycardia | Thyroid monitoring |
| Peripheral arterial disease | Possible worsening of symptoms | Clinical monitoring |
| Psoriasis | Beta-blockers can aggravate it | Discuss history before starting |
| Myasthenia gravis | Possible worsening of weakness | Specialist input |
| Severe kidney impairment | Limited data | Generally avoided or used with caution |
A meta-analysis by Salpeter and colleagues (2002) suggested that cardioselective beta-blockers are generally well tolerated in people with mild to moderate reactive airway disease or COPD. However, this does not apply to asthma, where nebivolol remains contraindicated.
Pregnancy and breastfeeding are also areas of caution. Beta-blockers can reduce placental blood flow and affect the baby's heart rate and blood sugar, so nebivolol is used in pregnancy only when clearly necessary.
Drug interactions
Some combinations with nebivolol can cause excessive slowing of the heart or a dangerous drop in blood pressure. A medication review by a doctor or pharmacist is an essential step before starting.
Verapamil and diltiazem, calcium channel blockers that also slow heart conduction, can cause severe bradycardia and heart block when combined with beta-blockers, particularly if given intravenously. Class I antiarrhythmics and amiodarone also require caution.
Drugs that inhibit CYP2D6, including some antidepressants such as fluoxetine and paroxetine, can increase nebivolol levels. Clonidine should not be stopped suddenly in a patient on a beta-blocker because of the risk of rebound hypertension.
Non-steroidal anti-inflammatory drugs such as ibuprofen may blunt the blood-pressure-lowering effect of antihypertensives in general. Patients should mention regular painkiller use to their prescriber.
Nebivolol, exercise and sport
Beta-blockers reduce maximum heart rate and may lower exercise capacity, particularly in endurance activities. Nebivolol's vasodilating action may make this effect less noticeable than with older drugs, but people should still expect some change in how training feels.
Under the WADA prohibited list, beta-blockers are banned in specific sports where steadiness matters, such as archery and shooting, both in and out of competition in some disciplines. Athletes in these sports who need a beta-blocker for a medical condition must apply for a therapeutic use exemption through UK Anti-Doping.
Nebivolol should never be stopped abruptly. Sudden withdrawal can cause rebound tachycardia, a rise in blood pressure and, in people with coronary disease, angina or heart attack. Any changes must be made gradually under medical supervision.
Seek urgent medical advice if you experience fainting, a very slow pulse, worsening breathlessness, wheezing or swelling of the ankles while taking nebivolol.
Editorial conclusions
Nebivolol is a highly selective beta-1 blocker with additional nitric oxide-mediated vasodilation, licensed in the UK for hypertension and for stable chronic heart failure in people aged 70 and over.
It is contraindicated in liver impairment, asthma, significant bradycardia, heart block without a pacemaker, acute heart failure and several other conditions.
Careful assessment of comorbidities and current medicines, and gradual dose changes under supervision, make it a safe option for the right patients.
Our editorial team suggests further reading on how blood pressure is assessed and treated in the UK, the effect of beta-blockers on training, and heart health checks for people over 40.
References
- Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225.
- Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54(16):1491–1499.
- Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137(9):715–725.
- Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1:CD002003.
- National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management (NG136). London: NICE; 2019.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2025. Montreal: WADA; 2025.
- https://steroidsbuy-online.com/item/pharma-test-p-100-mg-pharmacom-labs/
